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Objective. Opioid prescribing recently has come under intense scrutiny. However, longitudinal patterns of prescription opioid receipt in a population-based cohort of patients with chronic pain, such as those with rheumatoid arthritis (RA), have not been well characterized. The aim of this study was to examine both trends over time and variability in individual physician prescribing of short-term and long-term use of opioids.
Methods. We identified a cohort of RA patients based on 2006-2014 Medicare data and evaluated longitudinal time trends in "regular" use of opioids. A separate analysis conducted in 2014 assessed rheumatologistspecific variability in regular use of opioid prescriptions in patients with RA.
Results. We identified 97,859 RA patients meeting the eligibility criteria. The mean age of the patients was 67 years, 80% were female, 82% were white, and 12% were African American. The most commonly used opioids were those that combined acetaminophen with hydrocodone or propoxyphene. Regular opioid prescribing increased slowly but peaked in 2010 before propoxyphene was withdrawn from the market. Following the withdrawal of propoxyphene, receipt of hydrocodone and tramadol increased commensurately, and overall opioid use declined only slightly. Factors associated with regular use of opioids included younger age, female sex, African American race, back pain, fibromyalgia, anxiety, and depression. Variability between US rheumatologists (n 5 4,024) in prescribing the regular use of opioids for their RA patients was high; in the average rheumatologist's practice, 40% of RA patients used prescription opioids regularly. In almost half of the patients, at least some opioid prescriptions were written by a rheumatologist, and 14% received opioids that were co-prescribed concurrently by more than 1 physician.
Conclusion. In the US, opioid use in older patients with RA peaked in 2010 and is now declining slightly. Withdrawal of propoxyphene from the US market in 2010 had minimal effect on overall opioid use, because use of propoxyphene was replaced by increased use of other opioids.
Opioid use and addiction recently have drawn increasing scrutiny. An increase in the number of overdoses and addiction to both heroin and prescription pain relievers transpired over the past decade (1) (2) (3) , and this has been attributed to increased prescribing of opioids for the treatment of pain by physicians (4) . National trends suggest that the rate of opioid prescribing plateaued in 2010-2011 and then declined (4, 5) . Nevertheless, continuing concerns regarding opioid prescribing have spurred major initiatives across multiple federal agencies (6, 7) . What is unknown is whether patterns of opioid receipt among patients with well-defined medical causes of chronic pain follow similar national patterns. For example, the prescribing and opioid use patterns in patients with inflammatory arthritis, such as rheumatoid arthritis (RA), have not been well characterized.
We used health plan data to examine trends over time as well as variability in individual physician prescribing of opioids for short periods of time or long periods of time. We tested 3 main hypotheses: 1) that opioid use in patients with RA would follow national trends, 2) that patients with fibromyalgia and depression would be more likely to receive opioids, as would white patients, and 3) that after controlling for patient characteristics, individual rheumatologist prescribing of opioids for their RA patients would vary significantly, and that this interprovider variability would identify a class of "high opioid prescribers." These analyses were approved by the University of Alabama at Birmingham Institutional Review Board, and a Data Use Agreement with the Centers for Medicare and Medicaid Services governed use of the Medicare data.
PATIENTS AND METHODS
RA patient cohort and definition of opioid exposure. We used national Medicare data from 2006 to 2014 to identify a closed cohort of patients with RA, by requiring 2 International Classification of Diseases, Ninth Revision diagnosis codes (714.0, 714.2, and/or 714.81) assigned by a rheumatologist and separated by at least 7 days. Patients included in the analysis were required to have at least 6 consecutive observable months of coverage (enrolled in Medicare Part A, Part B, and Part D but not in Part C) prior to January 1, 2007. The closed cohort design was selected in order to better attribute trends in prescription opioid use to true changes over time rather than to a variable and changing case mix of RA patients, as might be problematic with an open cohort design in which patients could be added over time.
Follow-up started on January 1, 2007 and ended when Medicare coverage was lost, 90 days before death, or the end of study (December 31, 2014), whichever occurred first. Regular opioid use was defined as $3 filled prescriptions (written by any physician), or $1 opioid prescription filled for at least a 90-day supply in each calendar year, summed across all prescriptions. Regular opioid use status was assessed each calendar year in patients who continued to be followed up for the entirety of each 12-month interval. The opioids examined included hydrocodone, tramadol, oxycodone (alone or in combination with acetaminophen), propoxyphene, codeine, and other opioids (e.g., morphine). A separate class of "longacting opioid" medications was created and included extended-and sustained-release versions of oxycodone, morphine, methadone, or tramadol, as well as buprenorphine and fentanyl patches.
A second analysis focused on identifying the degree of variability in opioid use attributable to physician prescribing patterns was accomplished using 2014 data only. This analysis classified patients as regular users (as described above), nonusers (no filled opioid prescriptions in 2014), or intermittent users (only 1 or 2 prescriptions filled, and ,90 cumulative days of use). RA patients who received an RA diagnosis code from at least 1 rheumatologist encounter in 2014 were grouped by treating rheumatologist. Therefore, an individual patient with RA could be assigned to multiple rheumatologists if he or she met this criterion. In order to avoid excessive sampling variability, we restricted the 2014 analysis to rheumatologists with at least 10 RA patients enrolled in Medicare for the entire year.
We first estimated the proportion of each rheumatologist's RA patients who regularly received an opioid prescription and, separately, the proportion of regular opioid users for whom at least 1 opioid prescription was written by a rheumatologist. In the latter analysis, rheumatologists were grouped into deciles and ranked from lowest to highest based on their patients' opioid prescription receipt. Importantly, however, such patients could have received opioids from any provider (e.g., primary care physicians), and these prescriptions were included.
In order to quantify the proportion of patients who secured prescriptions from more than 1 physician, we operationalized opioid co-prescribing as regular prescribing of opioids to a patient with RA who filled at least 2 opioid prescriptions in 2014 written by more than 1 prescriber (of any specialty), when the pattern of filled prescriptions indicated that more than 1 physician was concurrently prescribing opioids for the patient. For example, if a patient filled 4 opioid prescriptions in 2014, with the first and third written by prescriber A and the second and fourth written by prescriber B, the patient would be classified as receiving co-prescribed opioids (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40152/abstract). In order to avoid the circumstance that 1 physician in a practice was simply covering for another, the definition of opioid co-prescribing did not include physicians who practiced together in the same group, identifiable in the data and being grouped under the same tax identification number.
Statistical analysis. Time trends in the proportion of patients with RA who were receiving prescription opioids regularly (regardless of whether the prescriber was a rheumatologist) were calculated by dividing the number of regular opioid recipients by the total number of RA patients being followed up during each 12-month period of time. The spline regression method was used to evaluate whether opioid use was increasing or decreasing over calendar time (8) , with 1 knot placed at the end of 2010 given that this was the date of propoxyphene withdrawal. The date of revision to the controlled substance schedule status of hydroxycodone (from schedule III to schedule II; October 2014) occurred at the end of the study period and was therefore ignored in this analysis.
The second analysis, focused on identifying the degree of variability in opioid use that might be attributable to 1 rheumatologist versus another, was accomplished using alternating logistic regression (9, 10) . This technique generates an estimate of a practice-based clustering effect (in essence, how likely the care of 1 patient was similar to that of another patient in the same physician practice). Model variables other than the specific rheumatologist were chosen based on clinical interest and review of the literature regarding other factors associated with chronic pain (e.g., low back pain, fibromyalgia) and concomitant conditions associated with pain (e.g., anxiety, depression). The interpretation of the odds ratio of the clustering effect estimated by the alternating logistic regression model is the likelihood that 2 patients within the same physician's practice would or would not be regular opioid users compared to 2 randomly selected patients from different physicians' practices. We adjusted for potential confounders that included comorbidities and socioeconomic status (proxied by median household income quartile according to the patient's residential zip code). Dual eligible status (qualifying for both Medicare and Medicaid, typically due to low income) or receipt of the Medicare Low-Income Subsidy was also examined. All analyses were completed using SAS version 9.4 (SAS Institute).
RESULTS
We identified 70,929 patients eligible for the time trend analysis based on meeting cohort eligibility criteria in 2007. In 2007, the most commonly used opioids were medications that combined acetaminophen with hydrocodone or propoxyphene (which was withdrawn from the US market in 2010). Over 2007-2014 (Figure 1 ), trends showed that overall opioid use increased slowly but significantly through 2010 (P , 0.0001, testing for non-zero slope), reached a peak in 2010, and decreased thereafter (P , 0.0001). Following the withdrawal of propoxyphene in 2010, use of hydrocodone and tramadol increased commensurately from 2010 to 2011 (P , 0.0001 for both).
In the 2014 analysis, we identified 240,750 RA patients with Medicare coverage who met the eligibility criteria. Of these, 97,859 patients (41%) were considered regular opioid users, 96,027 patients (40%) were considered nonusers, and the remaining 46,864 patients (19%) were considered intermittent opioid users. Among regular opioid users, 30% had some of their opioid prescriptions written by a rheumatologist, and an additional 16% had all of their opioid prescriptions written by a rheumatologist. Fourteen percent met the criteria for coprescription, with at least 2 prescriptions in 2014 coming from a physician other than a rheumatologist. Regular opioid users were younger (mean age 67 years), more likely to be female (80%), and more likely be African American (12%) compared to intermittent users or nonusers. The prevalence of all comorbidities was somewhat higher in regular opioid users compared to nonusers, but there were particularly notable contrasts for the receipt of opioids in patients who also had conditions of anxiety, depression, back pain, or soft tissue rheumatism (including fibromyalgia). Additionally, patients receiving opioids were more likely to receive biologic agents (40% of regular users versus 32% of nonusers) and to fill prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs) regularly ($3 fills among 34% of regular users versus 24% of nonusers) ( Table 1) . Among all regular opioid users, 19% (n 5 18,824) filled at least 1 prescription for a long-acting opioid in 2014.
In the subgroup analysis that used only 2014 data and clustered RA patients within physician practices, a total of 876 rheumatologists and their 2,100 RA patients were excluded because the rheumatologist cared for fewer than 10 RA patients. When patients were grouped by rheumatologist (n 5 4,024), there was substantial variability in their likelihood of receiving opioids. Figure 2 shows the overall likelihood of patients cared for by a TRENDS IN OPIOID USE IN RA PATIENTSparticular rheumatologist to receive opioids, regardless of whether the prescriber was the rheumatologist, another physician, or both. At the 50th percentile (median), 40% of patients received opioids regularly. The proportions of patients regularly taking opioids at the 25th and 75th percentiles were 31% and 48%, respectively. At the extremes (1st and 99th percentiles), 0-93% of RA patients within each rheumatologist's practice were treated with opioids. Figure 2 also shows the percentage of patients in whom at least 1 opioid prescription was from a rheumatologist, and 40% of patients had some or all of their opioid prescriptions written by a rheumatologist. Variability was found to be high when the opioid prescriptions written specifically by rheumatologists were examined, with a 4-fold difference in the likelihood of receiving an opioid from a rheumatologist among patients grouped in the lowest decile of opioid receipt compared to the highest decile. The difference between the percentage of patients qualifying as regular opioid users and the percentage of patients receiving opioids from their rheumatologist highlights the fact that at each decile of opioid use, rheumatologists wrote $1 prescription for only a minority of the patients who received opioids.
Physician clustering was significantly associated with opioid prescribing, and patients cared for by the same physician were 25% (95% confidence interval [95% CI] 18-32) more likely to be regular opioid users or nonusers, even after controlling for other patient characteristics. Other factors that were positively associated with regular opioid use included various comorbidities (coronary heart disease, peripheral vascular disorder, chronic pulmonary disease, malignancy, diabetes, back pain, fibromyalgia, anxiety, and depression) as well as treatment with biologic agents or NSAIDs, and use of durable medical equipment (e.g., wheelchair). Factors associated with a lower likelihood of patients being a regular opioid user were older age, male sex, white race, cerebrovascular disease, and hemiplegia. Conditional on an individual being a regular opioid user, the factors associated with taking opioids long term are shown in Table 2 . While many of the associations were similar to those in regular users, the trends were reversed for some covariates. Male sex and white race were associated with long-acting opioid use (versus short-acting opioid use), whereas NSAID use and low income were less likely to be associated with long-acting opioid use.
DISCUSSION
In the US, opioid use among older patients with RA peaked in 2010 and is now declining. By 2014, 41% of patients with RA were regular users of opioids.
Withdrawal of the second most commonly prescribed opioid (propoxyphene) from the US market in 2010 had minimal effect on overall opioid use, because the use of other medications (most notably hydrocodone and tramadol) increased. After an initial uptick in the use of hydrocodone, use slowly decreased over time, perhaps as higher-dose acetaminophen-containing products were slowly phased out from 2011 to 2014 due to regulatory issues. There was substantial variability between rheumatologists in the proportion of their RA patients who received opioids (either from the rheumatologist or from other doctors involved in their care), ranging from 0% to 93% in analyses before adjustment for patient characteristics.
There is general consistency between the findings in this study and those from prior studies in a single academic medical center, which showed that RA patients used more opioids compared to non-RA patients. In those studies, use of opioids increased over time in both RA and non-RA patients (11, 12) . Fibromyalgia was not significantly associated with opioid use (hazard ratio 1.84 [95% CI 0.58-5.88]), although the trends were suggestive and compatible with our results. Additionally, fibromyalgia and other comorbidities were classified only at baseline, which may have attenuated the associations of interest given the 10-year follow-up period in those studies. A larger study in older individuals with Medicare coverage (including Part D) that was conducted over 2007-2012 but was not focused on RA showed a general increase in the number of opioid prescriptions (13) . Consistent with our results, use of opioids peaked in 2011, with slight declines in both schedule III and a combination of schedule II/III opioids in 2012. Opioid use in this cohort of patients with Medicare coverage was quite variable by state, suggesting that some regional variability may be attributable to state regulations in opioid prescribing.
Our results suggest several contributors to the variability in opioid use among patients with RA. These include the prescribing practices of physicians, including rheumatologists and other physicians involved in patient care. There was high variability in the percentage of any given rheumatologist's patients who received opioids (0-93%). However, this unadjusted range summary does not take into account the patient-level characteristics that were also associated with opioid use. These included indicators of disease activity (i.e., diseasemodifying antirheumatic drug [DMARD] receipt), disease severity (e.g., claims for durable medical equipment, receipt of NSAIDs), other painful conditions (metastatic cancer or back pain), and other conditions for which opioid treatment is controversial or contraindicated, including fibromyalgia, anxiety, and depression. Once these patient characteristics were incorporated into the statistical model, affiliation with a particular rheumatologist was associated with a 25% greater or lesser likelihood that a patient with RA would receive opioids regularly. We note that the prescribers encompassed by the 25% finding include rheumatologists and other clinicians such as primary care providers, which somewhat dilutes the effect of an individual rheumatologist's prescribing practices, yielding a conservative estimate.
Effective pain control is often the highest priority as ranked by patients with RA (14) . However, randomized controlled trial evidence favoring regular opioid treatment for chronic noncancer pain is limited to shortterm studies of 6 months or fewer (6) . There are wellknown adverse effects (including overdose and addiction) applicable to some patients who receive opioids over the long term (15) (16) (17) , with fatal overdose affecting 0.04% of patients in a large Veterans Health Administration cohort (18) . Potential adverse effects of opioid use that are unique to RA patients include serious infections resulting in hospitalizations and nonvertebral fractures (19, 20) , although the causality remains unclear.
Weaker opioids such as tramadol may have a more favorable risk/benefit profile for short-term management of pain, and we observed increasing use of this drug over time, suggesting that physicians may be shifting patients from stronger to weaker opioids. Use of long-acting opioids remained flat over the entire study period. However, even for these medications, whether the benefits outweigh possible adverse effects requires individualized decision-making based on a personal assessment of the risk and benefit, as recommended by the Centers for Disease Control and Prevention (CDC) (15, 16) . Recent guidelines proposed by groups such as the American Society of Interventional Pain Physicians may be useful, although they are not specific to patients with arthritis (21) . A large database study such as the current study cannot directly assess whether the individual decisions made for each patient reflected the optimum balance of risk and benefit that is recommended by the CDC and other organizations. Nevertheless, the findings of statistical analysis raise the concern that some prescribing decisions may not have been appropriate. In particular, there is no evidence from trials that long-term opioid treatment is helpful in fibromyalgia (22) or in patients with depression and anxiety who may be at greater risk of harm, including overdose, when taking opioids (23) . Yet these 3 conditions were independently associated with opioid treatment. Even if these conditions were not construed as a strict contraindication, the positive association we observed raises concern that some patients likely received opioids when other interventions may have been more appropriate.
Alongside indications of potentially inappropriate prescribing, however, some patterns emerged suggesting a recognizable clinical response to ongoing disease activity. These are indicated by positive associations with DMARD and NSAID treatment. Prescribing for RA-related damage was suggested based on the association between opioid use and Medicare claims for durable medical equipment (e.g., wheelchair). Finally, it should be noted that the positive association between African American race and opioid receipt is opposite to the disparities reported in other settings (24) . We speculate that in some instances an opioid prescription may have been offered in lieu of making more challenging deliberations about management of long-term pain or as a result of failure to prescribe or inferior access to alternative treatment options for RA (e.g., biologic agents) that ultimately might have lower long-term risk or abuse potential.
The strengths of our study include use of a national data source that is highly generalizable to the vast majority of RA patients older than age 65 years in the US population (25) . We also had a sample that was large enough to group patients by physician to analyze within-provider variability, in order to examine the specialties in which the physicians were actually writing the opioid prescriptions (rheumatology versus other specialty) and to quantify co-prescribing of opioids, classified as receiving a prescription from more than 1 physician concurrently. Limitations to our study included a focus on only older patients, and our results therefore have uncertain generalizability to younger RA patients. Also, we did not have patient-level pain scores or other clinical information available and could not directly study the extent to which prescribing might be considered inappropriate. Finally, we recognize that although our closed cohort design reduced heterogeneity due to new patients becoming part of the analysis, who might have characteristics different from those of existing patients, trends in opioid prescribing for this cohort may have been impacted by the fact that patients were aging and may have been accruing RA-related damage that could justify opioid treatment in some patients with RA.
In summary, our results suggest substantial use of opioids in a population of older RA patients despite societal concerns regarding potential overprescribing in recent years. Rheumatologists played a significant prescribing role, although co-prescribing was relatively common (14%). Rheumatologists and other clinicians caring for patients with RA face a significant dilemma precisely because the options for treating pain remain problematic. The proven benefits of opioids for the treatment of RA-related pain, as well as other types of musculoskeletal pain syndromes, are restricted to trials of shorter duration and tend to be modest in magnitude (15, 26) and include the risk of side effects. The benefits of nonpharmacologic treatments are similarly modest in magnitude and limited to short-duration studies (27) . While nonpharmacologic alternatives avoid the risks of overdose and addiction, they remain at times inaccessible. Although the current findings are insufficiently granular to prove inappropriate practice, they do raise concerns. Moreover, they certainly reinforce the parallel needs for individualized care and increased efforts to develop new and effective pain interventions for patients with RA.
